Journal Article

DZNE-2024-01213

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Tumoricidal Activity and Side Effects of Radiolabeled Anti-NCAM [131I]-Iodine-ERIC1 in Neuroblastoma-Bearing Mice

Fischer, T. ; Dietlein, F. ; Bongartz, D. ; Klehr, M. ; Zimmermanns, B. ; Schmidt, M. ; Mohr, A. ; Mohr, F. ; Sudbrock, F. ; Krapf, P. ; Drzezga, A.DZNE* ; Dietlein, M. ; Schomäcker, K.

2024
Molecular Diversity Preservation International Basel

This record in other databases:    

Please use a persistent id in citations: doi:10.3390/ijms251910737

Abstract: Preliminary studies on a radioactive antibody against the neural cell adhesion molecule (NCAM) demonstrated a significant accumulation of [131I]I-ERIC1 in neuroblastoma tumor cells in mice. This study aims to validate the therapeutic efficacy and potential adverse effects of these radioactive immunoconjugates (RICs) in neuroblastoma-bearing mice. To determine the highest tolerated dose, healthy SCID mice received 1 to 22 MBq of [131I]I-ERIC1, with the survival time measured. Tumor response was evaluated by administering 0.8 to 22 MBq of [131I]I-ERIC1 to neuroblastoma-bearing mice and assessing tumor size and systemic toxicity through body weight, blood counts, and survival. It was observed that doses up to approximately 3 MBq per animal (150 MBq/kg) were well tolerated, whereas higher doses resulted in systemic toxicity and death. The neuroblastomas exhibited a dose-dependent response, with optimal therapeutic efficacy achieved at 1.8-2.5 MBq per animal (90-125 MBq/kg), significantly extending survival by a factor of five. The antibody ERIC1 is a promising vehicle for the transport of beta emitters into NCAM-positive tumor tissue. An optimal dosage of the [131I]I-ERIC1 antibody can be established with a balance of tumor-static effects and adverse effects, resulting in a marked extension of survival time.

Keyword(s): Animals (MeSH) ; Neuroblastoma: pathology (MeSH) ; Neuroblastoma: metabolism (MeSH) ; Neuroblastoma: drug therapy (MeSH) ; Mice (MeSH) ; Iodine Radioisotopes: adverse effects (MeSH) ; Cell Line, Tumor (MeSH) ; Neural Cell Adhesion Molecules: metabolism (MeSH) ; Humans (MeSH) ; Mice, SCID (MeSH) ; Xenograft Model Antitumor Assays (MeSH) ; Immunoconjugates: pharmacology (MeSH) ; Female (MeSH) ; Antibodies, Monoclonal: therapeutic use (MeSH) ; Antibodies, Monoclonal: pharmacology (MeSH)

---

Contributing Institute(s):

1. Positron Emissions Tomography (PET) (AG Boecker)

Research Program(s):

1. 353 - Clinical and Health Care Research (POF4-353) (POF4-353)

Appears in the scientific report 2024

---

Database coverage:
; ; ; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Physical, Chemical and Earth Sciences ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF >= 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---